Have a feature idea you'd love to see implemented?
Let us know!
HALO Halozyme Therapeutics Inc
Price (delayed)
$50.66
Market cap
$6.42B
P/E Ratio
19.41
Dividend/share
N/A
EPS
$2.61
Enterprise value
$7.73B
Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in
Highlights
The company's equity has surged by 92% YoY and by 63% QoQ
HALO's EPS has surged by 50% year-on-year and by 7% since the previous quarter
The stock's price to earnings (P/E) is 38% less than its 5-year quarterly average of 31.2 but 4.9% more than its last 4 quarters average of 18.5
Key stats
What are the main financial stats of HALO
Market
Valuations
Earnings
Shares outstanding
126.68M
Market cap
$6.42B
Enterprise value
$7.73B
Price to earnings (P/E)
19.41
Price to book (P/B)
22.28
Price to sales (P/S)
7.37
EV/EBIT
17.76
EV/EBITDA
14.88
EV/Sales
8.85
Revenue
$873.3M
EBIT
$435.46M
EBITDA
$519.77M
Free cash flow
$408.32M
Per share
Balance sheet
Liquidity
EPS
$2.61
Free cash flow per share
$3.21
Book value per share
$2.27
Revenue per share
$6.87
TBVPS
$8.77
Total assets
$1.97B
Total liabilities
$1.68B
Debt
$1.5B
Equity
$289.42M
Working capital
$854.44M
Debt to equity
5.19
Current ratio
7.41
Quick ratio
5.58
Net debt/EBITDA
2.53
Margins
Efficiency
Dividend
EBITDA margin
59.5%
Gross margin
80%
Net margin
38.6%
Operating margin
46%
Return on assets
18.1%
Return on equity
168.6%
Return on invested capital
20.1%
Return on capital employed
23.7%
Return on sales
49.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HALO stock price
How has the Halozyme Therapeutics stock price performed over time
Intraday
-6.41%
1 week
-12.9%
1 month
-14.48%
1 year
36.77%
YTD
37.07%
QTD
-11.5%
Financial performance
How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$873.3M
Gross profit
$698.25M
Operating income
$402.09M
Net income
$337.29M
Gross margin
80%
Net margin
38.6%
HALO's net income is up by 44% year-on-year and by 6% since the previous quarter
The company's operating income rose by 31% YoY and by 6% QoQ
The net margin has grown by 28% YoY and by 4.6% from the previous quarter
HALO's gross profit is up by 17% YoY and by 3.1% QoQ
Growth
What is Halozyme Therapeutics's growth rate over time
Valuation
What is Halozyme Therapeutics stock price valuation
P/E
19.41
P/B
22.28
P/S
7.37
EV/EBIT
17.76
EV/EBITDA
14.88
EV/Sales
8.85
HALO's EPS has surged by 50% year-on-year and by 7% since the previous quarter
The stock's price to earnings (P/E) is 38% less than its 5-year quarterly average of 31.2 but 4.9% more than its last 4 quarters average of 18.5
The company's equity has surged by 92% YoY and by 63% QoQ
HALO's price to book (P/B) is 44% lower than its 5-year quarterly average of 39.5 and 32% lower than its last 4 quarters average of 32.6
The price to sales (P/S) is 40% lower than the 5-year quarterly average of 12.2 but 13% higher than the last 4 quarters average of 6.5
The company's revenue rose by 13% YoY
Efficiency
How efficient is Halozyme Therapeutics business performance
Halozyme Therapeutics's return on assets has increased by 39% YoY and by 3.4% QoQ
HALO's return on invested capital is up by 31% year-on-year and by 3.1% since the previous quarter
HALO's return on sales is up by 24% year-on-year and by 4.8% since the previous quarter
The ROE has contracted by 13% YoY and by 13% from the previous quarter
Dividends
What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HALO.
Financial health
How did Halozyme Therapeutics financials performed over time
The company's total assets is 17% higher than its total liabilities
The company's current ratio rose by 13% YoY and by 12% QoQ
Halozyme Therapeutics's quick ratio has increased by 11% from the previous quarter and by 9% YoY
The company's equity has surged by 92% YoY and by 63% QoQ
Halozyme Therapeutics's debt to equity has decreased by 48% YoY and by 39% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.